Insights - Affimed’s (AFMD) ASH abstract for AFM13 was released today. The abstract (see here) covers AFM13 Phase 1 in relapsed/refractory CD30+ lymphoma patients. Affimed refers to this … Continue Reading
Premium: Read NowInsights - Earlier this week, Affimed announced a collaboration with Korean company NKMax to investigate the combination of AFM24, an EGFR engager, with autologous NK cell product … Continue Reading
Premium: Read NowInsights - AC Immune (ACIU) reported that semorinemab, their Phase 2 anti-tau candidate partnered with Genentech, did not meet its primary endpoint of reducing dementia symptoms compared to placebo. … Continue Reading
Premium: Read NowInsights - AC Immune announced a $80M ATM with Jeffries yesterday. With $280M in cash, good to last for at least 24 months, we do not think … Continue Reading
Read NowInsights - Merck announced data for their Phase 3 cough program this morning and it was rather disappointing. Cough effect in Phase 3 saw a large decrease from Phase … Continue Reading
Read NowInsights - Aerpio (ARPO) is developing a novel treatment for glaucoma that has Phase 2 data by the end of 2020. The company’s drug, razuprotafib, has shown to … Continue Reading
Premium: Read NowInsights - Affimed (AFMD) announced Q2 results today, which showed that the pipeline is progressing as planned. Below is an update for each candidate: AFM13: On Track … Continue Reading
Read Now
